| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.
|
Blood
|
2006
|
2.38
|
|
2
|
One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes.
|
Am J Pathol
|
2003
|
1.72
|
|
3
|
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.
|
Int Arch Allergy Immunol
|
2011
|
1.63
|
|
4
|
Mastocytosis: pathology, genetics, and current options for therapy.
|
Leuk Lymphoma
|
2005
|
1.61
|
|
5
|
Recent advances in the understanding of mastocytosis: the role of KIT mutations.
|
Br J Haematol
|
2007
|
1.47
|
|
6
|
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
|
J Allergy Clin Immunol
|
2010
|
1.46
|
|
7
|
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria.
|
Leuk Res
|
2003
|
1.39
|
|
8
|
Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease.
|
J Alzheimers Dis
|
2009
|
1.29
|
|
9
|
Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.
|
J Allergy Clin Immunol
|
2010
|
1.22
|
|
10
|
Dermoscopic features of skin lesions in patients with mastocytosis.
|
Arch Dermatol
|
2011
|
1.14
|
|
11
|
Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels.
|
Neurobiol Dis
|
2008
|
1.13
|
|
12
|
Flow cytometry criteria for systemic mastocytosis: bone marrow mast cell counts do not always count.
|
Am J Clin Pathol
|
2013
|
1.10
|
|
13
|
Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations.
|
Am J Clin Dermatol
|
2011
|
1.09
|
|
14
|
Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.
|
Int Arch Allergy Immunol
|
2002
|
1.07
|
|
15
|
Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis.
|
J Allergy Clin Immunol
|
2012
|
1.07
|
|
16
|
Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5.
|
J Immunol
|
2008
|
1.05
|
|
17
|
Evaluation of the WHO criteria for the classification of patients with mastocytosis.
|
Mod Pathol
|
2011
|
1.01
|
|
18
|
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.
|
Blood
|
2013
|
1.01
|
|
19
|
Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.
|
J Allergy Clin Immunol
|
2008
|
1.00
|
|
20
|
Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.
|
J Clin Oncol
|
2012
|
0.95
|
|
21
|
Childhood mastocytosis.
|
Curr Opin Pediatr
|
2012
|
0.90
|
|
22
|
Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis.
|
J Allergy Clin Immunol
|
2013
|
0.88
|
|
23
|
CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
|
Histopathology
|
2013
|
0.87
|
|
24
|
Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome.
|
PLoS One
|
2013
|
0.86
|
|
25
|
The European Competence Network on Mastocytosis (ECNM).
|
Wien Klin Wochenschr
|
2004
|
0.81
|
|
26
|
Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders.
|
Methods Cell Biol
|
2011
|
0.81
|
|
27
|
Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.
|
Immunotherapy
|
2011
|
0.80
|
|
28
|
European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.
|
Wien Klin Wochenschr
|
2012
|
0.80
|
|
29
|
Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis.
|
Ann Allergy Asthma Immunol
|
2013
|
0.80
|
|
30
|
The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal.
|
Eur J Endocrinol
|
2005
|
0.79
|
|
31
|
Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment.
|
Curr Allergy Asthma Rep
|
2006
|
0.79
|
|
32
|
Management of Anesthesia in Adult and Pediatric Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) Based on 726 Anesthetic Procedures.
|
Int Arch Allergy Immunol
|
2015
|
0.79
|
|
33
|
Flow cytometric analysis of intestinal intraepithelial lymphocytes in the diagnosis of refractory celiac sprue.
|
Eur J Gastroenterol Hepatol
|
2008
|
0.78
|
|
34
|
Calcium-pH crosstalks in the human mast cell line HMC-1: intracellular alkalinization activates calcium extrusion through the plasma membrane Ca2+-ATPase.
|
J Cell Biochem
|
2006
|
0.77
|
|
35
|
STI571 (Glivec) affects histamine release and intracellular pH after alkalinisation in HMC-1560, 816.
|
J Cell Biochem
|
2008
|
0.77
|
|
36
|
Influence of the tyrosine kinase inhibitors STI571 (Glivec), lavendustin A and genistein on human mast cell line (HMC-1(560)) activation.
|
J Cell Biochem
|
2008
|
0.76
|
|
37
|
Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis.
|
Haematologica
|
2011
|
0.75
|
|
38
|
Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis.
|
Br J Haematol
|
2003
|
0.75
|
|
39
|
Anemia, leukocytosis, abdominal pain, flushing, and bone and skin lesions.
|
Cleve Clin J Med
|
2012
|
0.75
|
|
40
|
Mastocytosis, Kounis syndrome and medical emergencies.
|
Intern Emerg Med
|
2014
|
0.75
|